Loading…
Loading…
PR Audio: BROOMFIELD, Colo., August 20, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the University of Arizona College of Medicine - Phoenix as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial.
BROOMFIELD, Colo., August 12, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers Extends Aclarion's IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for U.S. Patent Application titled “Multi-Voxel Prescription for Lumbar Disc Evaluation.
Aclarion, Inc. (ACON) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $2.75 per share a year ago.
PR Audio: BROOMFIELD, Colo., August 04, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Partnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery and spine care networks Goodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery training and clinical research Availability of Nociscan in Indiana reflects Company's focus on expansion and adding to its growing base of provider sites across the country BROOMFIELD, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology.
PR Audio: Broomfield, CO, July 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.